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Autophagy is a lysosomal degradation pathway that is essential for survival, differentiation, devel-
opment, and homeostasis. Autophagy principally serves an adaptive role to protect organisms 
against diverse pathologies, including infections, cancer, neurodegeneration, aging, and heart 
disease. However, in certain experimental disease settings, the self-cannibalistic or, paradoxically, 
even the prosurvival functions of autophagy may be deleterious. This Review summarizes recent 
advances in understanding the physiological functions of autophagy and its possible roles in the 
causation and prevention of human diseases.Introduction
Fasting has been an integral part of health and healing practices 
throughout the recorded history of mankind. This ancient tradition 
may be partially rooted in a cellular process we are now beginning 
to understand in modern scientific terms. One of the most evolu-
tionarily conserved cellular responses to organismal fasting is the 
activation of the lysosomal degradation pathway of autophagy, a 
process in which the cell self-digests its own components. This 
self-digestion not only provides nutrients to maintain vital cellular 
functions during fasting but also can rid the cell of superfluous 
or damaged organelles, misfolded proteins, and invading micro-
organisms. Interestingly, self-digestion by autophagy—a process 
that is potently triggered by fasting—is now emerging as a central 
biological pathway that functions to promote health and  longevity.
The Autophagic Pathway
Autophagy (from the Greek, “auto” oneself, “phagy” to eat) refers 
to any cellular degradative pathway that involves the delivery of 
cytoplasmic cargo to the lysosome. At least three forms have 
been identified—chaperone-mediated autophagy, microau-
tophagy, and macroautophagy—that differ with respect to their 
physiological functions and the mode of cargo delivery to the lyso-
some. This Review will focus on macroautophagy (herein referred 
to as autophagy), the major regulated catabolic mechanism that 
eukaryotic cells use to degrade long-lived proteins and organelles. 
This form of autophagy involves the delivery of cytoplasmic cargo 
sequestered inside double-membrane vesicles to the lysosome 
(Figure 1). Initial steps include the formation (vesicle nucleation) 
and expansion (vesicle elongation) of an isolation membrane, 
which is also called a phagophore. The edges of the phagophore 
then fuse (vesicle completion) to form the autophagosome, a dou-
ble-membraned vesicle that sequesters the cytoplasmic material. 
This is followed by fusion of the autophagosome with a lysosome 
to form an autolysosome where the captured material, together 
with the inner membrane, is degraded (Figure 1).Autophagy occurs at low basal levels in virtually all cells to 
perform homeostatic functions such as protein and organelle 
turnover. It is rapidly upregulated when cells need to generate 
intracellular nutrients and energy, for example, during starva-
tion, growth factor withdrawal, or high bioenergetic demands. 
Autophagy is also upregulated when cells are preparing to 
undergo structural remodeling such as during developmental 
transitions or to rid themselves of damaging cytoplasmic com-
ponents, for example, during oxidative stress, infection, or pro-
tein aggregate accumulation. Nutritional status, hormonal fac-
tors, and other cues like temperature, oxygen concentrations, 
and cell density are important in the control of autophagy. The 
molecular cascade that regulates and executes autophagy 
has been the subject of recent, comprehensive reviews (Klion-
sky, 2007; Maiuri et al., 2007a; Mizushima and Klionsky, 2007; 
Rubinsztein et al., 2007).
One of the key regulators of autophagy is the target of rapamy-
cin, TOR kinase, which is the major inhibitory signal that shuts 
off autophagy in the presence of growth factors and abundant 
nutrients. The class I PI3K/Akt signaling molecules link recep-
tor tyrosine kinases to TOR activation and thereby repress 
autophagy in response to insulin-like and other growth factor 
signals (Lum et al., 2005). Some of the other regulatory mole-
cules that control autophagy include 5′-AMP-activated protein 
kinase (AMPK), which responds to low energy; the eukaryotic 
initiation factor 2α (eIF2α), which responds to nutrient starvation, 
double-stranded RNA, and endoplasmic reticulum (ER) stress; 
BH3-only proteins that contain a Bcl-2 homology-3 (BH3) domain 
and disrupt Bcl-2/Bcl-XL inhibition of the Beclin 1/class III PI3K 
complex; the tumor suppressor protein, p53; death-associated 
protein kinases (DAPk); the ER-membrane-associated protein, 
Ire-1; the stress-activated kinase, c-Jun-N-terminal kinase; the 
inositol-trisphosphate (IP3) receptor (IP3R); GTPases; Erk1/2; 
ceramide; and calcium (Criollo et al., 2007; Maiuri et al., 2007a; 
Meijer and Codogno, 2006; Rubinsztein et al., 2007).Cell 132, January 11, 2008 ©2008 Elsevier Inc. 27
Downstream of TOR kinase, there are more than 20 genes 
in yeast (known as the ATG genes) that encode proteins (many 
of which are evolutionarily conserved) that are essential for the 
execution of autophagy (Mizushima and Klionsky, 2007) (Figure 
1). These include a protein serine/threonine kinase complex that 
responds to upstream signals such as TOR kinase (Atg1, Atg13, 
Atg17), a lipid kinase signaling complex that mediates vesicle 
nucleation (Atg6, Atg14, Vps34, and Vps15), two ubiquitin-like 
conjugation pathways that mediate vesicle expansion (the Atg8 
and Atg12 systems), a recycling pathway that mediates the dis-
assembly of Atg proteins from mature autophagosomes (Atg2, 
Atg9, Atg18), and vacuolar permeases that permit the efflux of 
amino acids from the degradative compartment (Atg22). In mam-
mals, proteins that act more generally in lysosomal function are 
required for proper fusion with autophagosomes—such as the 
lysosomal transmembrane proteins, LAMP-2 and CLN3—and 
for the degradation of autophagosomal contents, such as the 
lysosomal cysteine proteases, cathepsins B, D, and L (Table 1).
The identification of signals that regu-
late autophagy and genes that execute 
autophagy has facilitated detection and 
manipulation of the autophagy pathway. 
Phosphatidylethanolamine (PE) conju-
gation of yeast Atg8 or mammalian LC3 
during autophagy results in a nonsoluble 
form of Atg8 (Atg8-PE) or LC3 (LC3-II) 
that stably associates with the autopha-
gosomal membrane (Figure 1). Conse-
quently, autophagy can be detected bio-
chemically (by assessing the generation 
of Atg8-PE or LC3-II) or microscopically 
(by observing the localization pattern 
of fluorescently tagged Atg8 or LC3) 
(Mizushima and Klionsky, 2007). These 
approaches must be coupled with ancil-
lary measures to discriminate between two physiologically 
distinct scenarios—increased autophagic flux without impair-
ment in autophagic turnover (i.e., an increased “on-rate”) versus 
impaired clearance of autophagosomes (i.e., a “decreased off-
rate”), which results in a functional defect in autophagic catabo-
lism (Figure 2).
Autophagy can be pharmacologically induced by inhibiting 
negative regulators such as TOR with rapamycin (Rubinsztein 
et al., 2007); the antiapoptotic proteins Bcl-2 and Bcl-XL that 
bind to the mammalian ortholog of yeast Atg6, Beclin 1, with 
ABT-737 (Maiuri et al., 2007b); IP3R with xestospongin B, an 
IP3R antagonist; or lithium, a molecule that lowers IP3 levels 
(Criollo et al., 2007). Autophagy can be pharmacologically 
inhibited by targeting the class III PI3K involved in autopha-
gosome formation with 3-methyladenine or by targeting the 
fusion of autophagosomes with lysosomes, using inhibitors of 
the lysosomal proton pump such as bafilomycin A1 or lysoso-
motropic alkalines such as chloroquine and 3-hydroxychloro-
Figure 1. The Cellular, Molecular, and 
Physiological Aspects of Autophagy
The cellular events during autophagy follow dis-
tinct stages: vesicle nucleation (formation of the 
isolation membrane/phagophore), vesicle elonga-
tion and completion (growth and closure), fusion of 
the double-membraned autophagosome with the 
lysosome to form an autolysosome, and lysis of 
the autophagosome inner membrane and break-
down of its contents inside the autolysosome. This 
process occurs at a basal level and is regulated by 
numerous different signaling pathways (see text 
for references). Shown here are only the regula-
tory pathways that have been targeted pharma-
cologically for experimental or clinical purposes. 
Inhibitors and activators of autophagy are shown 
in red and green, respectively. At the molecular 
level, Atg proteins form different complexes that 
function in distinct stages of autophagy. Shown 
here are the complexes that have been identified 
in mammalian cells, with the exception of Atg13 
and Atg17 that have only been identified in yeast. 
The autophagy pathway has numerous proposed 
physiological functions; shown here are functions 
revealed by in vivo studies of mice that cannot un-
dergo autophagy (see Table 1).28 Cell 132, January 11, 2008 ©2008 Elsevier Inc.
Table 1. Phenotypes of Mice with Mutations in Autophagy Genes
Genotype (Organ) Phenotype Reference
Mutations Affecting Formation of Autophagosomes
atg4C−/− (all tissues) Diaphragm-specific autophagy defect during starvation. Increased chemically induced 
fibrosarcomas.
Marino et al., 2007
atg5−/− (all tissues) Death within 24 hr after birth presumably due to nutrient and energy depletion. Suckling 
defect. Increased numbers of apoptotic cells in embryos.
Kuma et al., 2004; Qu et 
al., 2007
atg5F/F:nestin-Cre (neurons) Progressive neurodegeneration associated with ubiquitinated protein aggregates and 
inclusion bodies.
Hara et al., 2006
atg5F/F:MLC2v-Cre (cardio-
myocytes)
Normal hearts under basal conditions but increased pressure load-induced ventricular 
dilatation and heart failure.
Nakai et al., 2007
atg5F/F:MerCreMer (car-
diomyocytes, tamoxifen-
inducible)
Ventricular dilatation, contractile dysfunction, disorganized sarcomeres, and misaligned/
aggregated mitochondria after tamoxifen injection.
Nakai et al., 2007
atg5−/− (dendritic cells) Normal dendritic cell development but impaired autophagic delivery to endosomal Toll-
like receptors and interferon production during virus infection.
Lee et al., 2007
atg5−/− (T cells) Increased spontaneous apoptosis in vivo (CD8+ T cells) and defective activation-induced 
proliferation in vitro (CD4+ and CD8+ T cells).
Pua et al., 2007
atg6/beclin 1−/− (all tissues) Abnormal ectodermal layer with reduced cavitation and early embryonic lethality. Yue et al., 2003; Qu et 
al., 2007
atg6/beclin 1+/− (all tissues) Increased frequency of spontaneous malignancies (especially lymphomas) and mam-
mary neoplasia. Decreased pressure overload-induced heart failure. Decreased cardiac 
injury during ischemia/reperfusion.
Qu et al., 2003; Yue et al., 
2003; Zhu et al., 2007; 
Matsui et al., 2007
atg7−/− (all tissues) Death within 24 hr after birth presumably due to nutrient and energy depletion. Komatsu et al., 2005
atg7F/F:nestin-Cre (neurons) Progressive neurodegeneration associated with ubiquitinated protein aggregates and 
inclusion bodies. Increased frequency of TUNEL+ neurons.
Komatsu et al., 2006
atg7F/F:Mx1-Cre (liver) Ubiquitinated protein aggregates, deformed mitochondria, and aberrant membranous 
structures in hepatocytes. Reduced removal of peroxisomes after chemical treatment.
Komatsu et al., 2005; 
Iwata et al., 2006
ambra1−/− (all tissues) Decreased autophagy, increased apoptosis, and increased cell proliferation in fetal brain. 
Neural tube defects and embryonic death. 
Fimia et al., 2007
bif-1−/− Increased frequency of spontaneous lymphomas and solid tumors. Takahashi et al., 2007
Mutations Affecting Lysosomal Clearance of Autophagosomes
lamp-2−/− (all tissues) Autophagosome accumulation in multiple tissues. Impaired hepatocyte long-lived pro-
tein degradation. Vacuolar cardiomyopathy and skeletal myopathy.
Tanaka et al., 2000
cln3 (all tissues) Juvenile neuronal ceroid lipofuscinosis, with autophagic vacuolization and LC3-I to LC3-
II conversion.
Cao et al., 2006
cathepsin D−/− (all tissues) Neuronal ceroid lipofuscinosis with autophagic vacuolization and LC3-I to LC3-II conver-
sion. Bax knockout reduces enhanced apoptosis but not autophagic degeneration and 
neuronal loss.
Koike et al., 2005; 
Shacka et al., 2007
cathepsin B−/−L−/− (all tissues) Severe brain atrophy with enhanced apoptosis, autophagic vacuolization, and LC3-I to 
LC3-II conversion.
Felbor et al., 2002; Koike 
et al., 2005quine (Rubinsztein et al., 2007) (Figure 1). It should be noted 
that all of these pharmacological agents lack specificity for the 
autophagy pathway. Therefore, although some of these agents 
such as rapamycin, lithium, and chloroquine are clinically 
available and may be helpful for treating diseases associated 
with autophagy deregulation, genetic approaches to inhibiting 
autophagy—for example, knockout of ATG genes by homolo-
gous recombination or knockdown by small-interfering RNA 
(siRNA)—have yielded more conclusive information about the 
biologic roles of autophagy in health and disease.
Physiological Functions of Autophagy
Autophagy Defends against Metabolic Stress
Autophagy is activated as an adaptive catabolic process 
in response to different forms of metabolic stress, including 
nutrient deprivation, growth factor depletion, and hypoxia. This bulk form of degradation generates free amino and fatty acids 
that can be recycled in a cell-autonomous fashion or delivered 
systemically to distant sites within the organism. Presumably, 
the amino acids generated are used for the de novo synthesis 
of proteins that are essential for stress adaptation. The molec-
ular basis for the recycling function of autophagy has only 
recently begun to be defined with the identification of yeast 
Atg22 as a vacuolar permease required for the efflux of amino 
acids resulting from autophagic degradation (Mizushima and 
Klionsky, 2007). It is presumed that the recycling function of 
autophagy is conserved in mammals and other higher organ-
isms, although direct data proving this concept are lacking.
The amino acids liberated from autophagic degradation can 
be further processed and, together with the fatty acids, used 
by the tricarboxylic acid cycle (TCA) to maintain cellular ATP 
production. The importance of autophagy in fueling the TCA Cell 132, January 11, 2008 ©2008 Elsevier Inc. 29
cycle is supported by studies showing that certain phenotypes 
of autophagy-deficient cells can be reversed by supplying 
them with a TCA substrate such as pyruvate (or its membrane-
permeable derivative methylpyruvate). For example, meth-
ylpyruvate can maintain ATP production and survival in growth 
factor-deprived autophagy-deficient cells that would otherwise 
quickly die (Lum et al., 2005). It can also restore ATP produc-
tion, the generation of engulfment signals, and effective corpse 
removal in autophagy-deficient cells during embryonic devel-
opment (Qu et al., 2007).
This role of autophagy in maintaining macromolecular 
synthesis and ATP production is likely a critical mechanism 
underlying its evolutionarily conserved prosurvival function. 
Gene knockout or knockdown studies in diverse phyla provide 
strong evidence that autophagy plays an essential function 
in organismal survival during nutrient 
stress (Maiuri et al., 2007a). Yeast cells 
lacking ATG genes display reduced tol-
erance to nitrogen or carbon deprivation 
and are defective in starvation-induced 
sporulation. Similarly, null mutations in 
ATG genes in slime molds limit viability 
and differentiation during nutrient depri-
vation. Loss-of-function mutations in 
ATG genes in plants reduce tolerance to 
nitrogen or carbon depletion, resulting 
in enhanced chlorosis, reduced seed 
set, and accelerated leaf senescence 
(Bassham et al., 2006). Furthermore, 
siRNA-mediated knockdown of atg 
genes in nematodes decreases survival 
during starvation (Kang et al., 2007). 
Autophagy also enables mammals to 
withstand nutrient depletion (Table 1). 
Mice lacking either atg5−/− or atg7−/− are 
born at normal Mendelian ratios yet die 
within hours after birth, presumably due to their inability to 
adapt to the neonatal starvation period.
Thus, a critical physiological role of autophagy appears 
to be the mobilization of intracellular energy resources to 
meet cellular and organismal demands for metabolic sub-
strates. The requirement for this function of autophagy is 
not limited to settings of nutrient starvation. Because growth 
factors are often required for nutrient uptake, loss of growth 
factor signaling can result in reduced intracellular metabo-
lite concentrations and activation of autophagy-dependent 
survival mechanisms (Lum et al., 2005). It is also possible 
that in certain settings, especially when cells suddenly 
have high metabolic needs, autophagy may be needed in a 
cell-autonomous fashion to generate sufficient intracellular 
metabolic substrates to maintain cellular energy homeosta-
Figure 2. Alterations in Different Stages of 
Autophagy Have Different Consequences
An increased on-rate of autophagy occurs in re-
sponse to stress signals, resulting in increased 
autophagosomal and autolysosomal accumula-
tion and successful execution of the adaptive 
physiological functions of autophagy. In certain 
disease states or upon treatment with lysosomal 
inhibitors, there is a reduced off-rate resulting in 
impaired lysosomal degradation of autophago-
somes. This results in increased autophagosomal 
accumulation and adverse pathophysiological 
consequences related to unsuccessful comple-
tion of the autophagy pathway. A decreased 
on-rate is observed if signaling activation of au-
tophagy is defective or mutations are present in 
ATG genes. This results in decreased autopha-
gosomal accumulation, the accumulation of pro-
tein aggregates and damaged organelles, and 
pathophysiological consequences related to de-
ficient protein and organelle turnover. The physi-
ological and pathophysiological consequences 
listed for “increased on-rate,” “reduced off-rate,” 
and “decreased on-rate” are based on knockout 
studies of the ATG genes in model organisms.30 Cell 132, January 11, 2008 ©2008 Elsevier Inc.
sis. This hypothesis may explain why there are high levels of 
autophagy in the mouse heart and diaphragm immediately 
following birth (Kuma et al., 2004).
Autophagy Works as a Cellular Housekeeper
The repertoire of routine housekeeping functions performed 
by autophagy includes the elimination of defective proteins 
and organelles, the prevention of abnormal protein aggregate 
accumulation, and the removal of intracellular pathogens. 
Such functions are likely critical for autophagy-mediated pro-
tection against aging, cancer, neurodegenerative diseases, 
and infection. Although some of these functions overlap with 
those of the ubiquitin-proteosome system—the other major 
Figure 3. Autophagy, Protein Quality Control, and Neurodegeneration
Normal proteins are routinely turned over by different protein degradation sys-
tems, including the ubiquitin-proteasome system (UPS), chaperone-mediated 
autophagy (CMA), and macroautophagy (referred to herein as “autophagy”). 
In autophagy-deficient neurons, there is an accumulation of ubiquitinated pro-
tein aggregates that is associated with neurodegeneration. Similar effects of 
autophagy deficiency are observed in other postmitotic cells (hepatocytes, 
cardiomyocytes) under basal conditions. Proteins altered by mutations (such 
as polyglutamine expansion tracts), posttranslational modifications, or stress 
(such as oxidative stress, UV irradiation, toxins) undergo a conformational 
change, are recognized by molecular chaperones, and are either refolded and 
repaired or delivered to protein degradation systems (usually UPS or CMA). If 
these protein degradation systems are impaired or if the altered proteins form 
oligomeric complexes that cannot be recognized by the UPS or CMA, au-
tophagy may be the primary route for the removal of these abnormal and po-
tentially toxic proteins. Impaired autophagy is associated with the formation 
of protein aggregates and increased neurodegeneration. The mechanisms by 
which abnormal proteins and impaired autophagy result in neurodegeneration 
are not known.cellular proteolytic system—the autophagy pathway is uniquely 
capable of degrading entire organelles such as mitochondria, 
peroxisomes, and ER as well as intact intracellular microor-
ganisms. Further, the relative role of the autophagy-lysosome 
system in protein quality control—i.e., in preventing the intra-
cellular accumulation of altered and misfolded proteins—may 
be greater than previously anticipated.
Tissue-specific disruption of ATG genes has revealed a critical 
role for basal autophagy in protein quality control in murine post-
mitotic cells (Table 1). Atg7 deletion in hepatocytes, atg5 and atg7 
deletion in neurons, and atg5 deletion in cardiomyocytes result 
in the accumulation of ubiquitin-positive protein aggregates in 
inclusion bodies that are associated with cellular degeneration. 
Such abnormalities have not been reported for atg5-deficient 
dendritic cells or T lymphocytes, perhaps because autophagy 
is less important for the waste management of rapidly prolifer-
ating cells. Moreover, the underlying mechanism for the accu-
mulation of ubiquitin-positive aggregates in certain autophagy 
knockout mouse tissues remains unknown. Cytoplasmic accu-
mulation of diffuse ubiquitinated proteins precedes the accu-
mulation of aggregates in atg5-deficient neurons (Hara et al., 
2006). Thus, aggregate formation may be a secondary result of 
a general defect in protein turnover rather than a failure of basal 
autophagy to clear aggregates that are formed constitutively in 
normal conditions (Mizushima and Klionsky, 2007). According to 
such a model, in the absence of autophagy, the turnover of cyto-
solic proteins is impaired, increasing their propensity to become 
damaged and misfolded and subsequently ubiquitinated and 
aggregated (Figure 3). It is not yet clear whether the ubiquit-
inated proteins are autophagically sequestered in a random, 
nonselective fashion, or whether they are selectively targeted 
to the autophagosome by a mechanism involving p62/SQSTM1, 
an adaptor protein that binds both ubiquitin and LC3 (Pankiv et 
al., 2007).
Unlike proteasomal degradation, the autophagic breakdown 
of substrates is not limited by steric considerations and there-
fore autophagy can sequester and degrade entire organelles. In 
yeast, autophagy participates in the selective removal of super-
fluous peroxisomes (pexophagy) generated when cells adapt 
to glucose metabolism (Nair and Klionsky, 2005) and perhaps 
in the elimination of damaged mitochondria (mitophagy), as atg 
mutant yeast accumulate dysfunctional mitochondria (Zhang et 
al., 2007). Selective degradation of peroxisomes or mitochondria 
was reported in hepatocytes isolated from clofibrate-treated or 
starved rats, respectively (Kim et al., 2007), but until recently the 
importance of these forms of selective autophagy in mammalian 
physiology was unclear. However, under steady-state conditions, 
atg7-deficient mouse hepatocytes accumulate peroxisomes, 
deformed mitochondria, and aberrant concentric membranous 
structures that are contiguous with the ER, and during chemi-
cal treatment, atg7-deficient mouse livers display a defect in the 
removal of excess peroxisomes (Table 1). Furthermore, agents 
that promote ER stress induce the selective autophagy of ER 
membranes (reticulophagy) both in yeast and in mammalian cells 
(Klionsky, 2007). Taken together, these observations indicate 
that basal and induced autophagy are likely important for the 
physiological control of number and quality of organelles across 
diverse phyla and function to eliminate superfluous and damaged Cell 132, January 11, 2008 ©2008 Elsevier Inc. 31
organelles. Defined or candidate signals for selective organelle 
recognition by autophagy include the peroxisome membrane tag, 
Pex14, an outer mitochondrial membrane protein, Uth1p, in yeast 
(Mizushima and Klionsky, 2007), and the mitochondrial perme-
ability transition in mammalian cells (Kim et al., 2007).
Autophagy May Be a Guardian of the Genome
Recent studies in ATG gene-deficient immortalized epithelial cells 
indicate that the autophagic machinery can limit DNA damage and 
chromosomal instability (Mathew et al., 2007a). Because these 
studies used cells with simultaneous defects in DNA checkpoints 
and apoptosis pathways, it is not yet known whether autophagy 
plays a primary function in preventing genomic instability in nor-
mal cells. However, in view of known functions of autophagy in 
energy homeostasis and in protein and organelle quality control, 
this seems likely. Such a role of autophagy would mechanistically 
link effects on the prevention of tumor initiation, tumor progres-
sion, aging, and neurodegeneration. The precise mechanisms by 
which deficient autophagy compromises genomic stability are 
unclear. Failure to control the damage of checkpoint or repair pro-
teins, deregulated turnover of centrosomes, insufficient energy 
for proper DNA replication and repair, and excessive generation 
of reactive oxygen species due to inefficient removal of dam-
aged mitochondria are possible alterations that may contribute 
to genomic instability in autophagy-defective cells (Jin and White, 
2007; Mathew et al., 2007a).
Autophagy in Life and Death Decisions of the Cell
Under most circumstances, autophagy constitutes a stress 
adaptation pathway that promotes cell survival. An appar-
ent paradox is that autophagy is also considered a form 
of nonapoptotic programmed cell death called “type II” or 
“autophagic” cell death. This type of cell death has been his-
torically defined by morphological criteria, but it is now clear 
that the mere presence of autophagosomes in dying cells is 
insufficient to distinguish “cell death with autophagy” from 
“cell death by autophagy.” The knockdown of ATG genes has 
recently defined whether autophagy functions in the execution 
of cell death in different settings (see Maiuri et al., 2007a for 
detailed review).
It is not yet understood what factors determine whether 
autophagy is cytoprotective or cytotoxic and whether cyto-
toxicity occurs as the result of self-cannibalism, the specific 
degradation of cytoprotective factors, or other as of yet unde-
fined mechanisms (for an extensive discussion, see Maiuri et 
al., 2007a). The most intuitive mechanism is self-cannibalism. 
However, cells subjected to prolonged growth factor depriva-
tion or shortage of glucose and oxygen can lose the major-
ity of their mass via autophagy and fully recover when placed 
in optimal culture conditions (Degenhardt et al., 2006; Lum et 
al., 2005), suggesting that cell death via autophagy may not 
be simply a matter of crossing a quantitative threshold of self-
digestion. Although autophagy can independently influence life 
and death decisions of the cell (by being cytoprotective or self-
destructive), it is also intricately linked to apoptotic death path-
ways. Factors that may control the cellular “decision” between 
the two responses include potentially variable thresholds for 
each process, molecular links that coordinately regulate apop-
tosis and autophagy, and mutual inhibition or activation of each 
pathway by the other (see Maiuri et al., 2007a for details).32 Cell 132, January 11, 2008 ©2008 Elsevier Inc.There is no evidence currently that the ATG genes promote 
programmed cell death that occurs physiologically in vivo, 
for instance during development. In fact, nematodes lacking 
bec-1, an ortholog of atg6/beclin 1, and mice lacking beclin 1 
or atg5 display increased, rather than decreased, numbers of 
apoptotic cells in embryonic tissues (Qu et al., 2007; Takacs-
Vellai et al., 2005; Yue et al., 2003). Given the recently identi-
fied role of ATG genes in facilitating the heterophagic removal 
of apoptotic corpses (Qu et al., 2007) (Figure 1C), it is not yet 
certain whether the increased numbers of apoptotic cells in 
autophagy-deficient embryos represent increased cell death 
events, delayed clearance of dead cells, or a combination of 
the two. Perhaps clearer evidence for a prosurvival function 
of autophagy in vivo is provided by tissue-specific ATG gene 
knockout studies—for example the neuron-specific knockout 
of atg5 or atg7 and T cell-specific knockout of atg5—where 
increased apoptosis is observed in mature animals (Table 1).
The intricate interplay between autophagy and life and death 
decisions of the cell mirrors some of the complexities in deci-
phering the roles of autophagy in human diseases and their 
treatments. For decades, pathologists have noted ultrastruc-
tural features of autophagy in a cornucopia of human diseases, 
including infections, neurodegenerative and myodegenerative 
diseases, cardiomyopathies, and cancer (de Duve and Wattiaux, 
1966; Martinez-Vicente and Cuervo, 2007). These findings were 
largely either ignored or presumed to reflect a causative role of 
autophagy in cellular degeneration and disease. The inability 
to distinguish between defective autophagy (with decreased 
removal of autophagosomes) and increased autophagic activ-
ity (with increased formation of autophagosomes) further con-
founded the pathophysiological interpretation of autophagosome 
accumulation in tissue samples. Now, with the identification of 
signaling pathways that regulate autophagy, evolutionarily con-
served gene products that mediate autophagy, and methods to 
distinguish between increased on-rates versus decreased off-
rates of autophagy, pharmacological, genetic, and biochemical 
approaches are being used to redefine the role of autophagy in 
the pathogenesis of human diseases.
Autophagy in Disease
Autophagy and Neurodegenerative Diseases
Early reports demonstrating that autophagosomes accumulate 
in the brains of patients with diverse neurodegenerative dis-
eases, including Alzheimer’s disease, transmissible spongiform 
encephalopathies, Parkinson’s disease, and Huntington’s dis-
ease (reviewed in Rubinsztein et al., 2007; Williams et al., 2006), 
led to the initial hypothesis that autophagy contributed to the 
pathogenesis of these disorders. In mice with cerebellar degen-
eration due to mutations in glutamate receptor, autophagy was 
also postulated to be a mechanism of nonapoptotic cell death 
(Yue et al., 2002). In contrast, more recent studies provide com-
pelling evidence that at least in model organisms autophagy 
protects against diverse neurodegenerative diseases and that 
the accumulation of autophagosomes primarily represents the 
activation of autophagy as a beneficial physiological response 
or, in the case of Alzheimer’s disease, the consequence of a 
defect in autophagosomal maturation (Martinez-Vicente and 
Cuervo, 2007; Rubinsztein et al., 2007; Williams et al., 2006).
Table 2. Germline or Somatic Mutations that Affect Autophagy in Human Disease
Affected Protein Disease and Putative Link to Autophagy Reference
Gene Products Required for Autophagy
Atg16L1 (germline) Crohn’s disease (a type of inflammatory bowel disease), possibly due to altered 
autophagy-dependent immune regulation or bacterial clearance. 
Massey and Parkes, 
2007
Beclin 1a (somatic; monoallelic 
deletions)
Breast, ovarian, and prostate cancer, possibly due to genomic instability or altered cell 
growth control associated with reduced autophagy.
Liang et al., 1999
UVRAG (somatic; monoallelic 
deletions)
Colon cancer, possibly due to mechanisms similar to those observed with beclin 1 dele-
tion.
Liang et al., 2006
Genes Products Involved in Autophagosomal Sequestration, Movement, or Maturation
P62/SQSTM1 (mutations in 
ubiquitin-binding site)
Paget disease (abnormal bone loss associated with increased osteoclast activity), pos-
sibly due to impaired autophagy of ubiquitinated proteins.
Lucas et al., 2006
Dynactin subunit p150glued Motor neuron disease with spinal and bulbar muscular atrophy, possibly due to abnormal 
movement of autophagosomes.
Puls et al., 2005
CLN3a Juvenile onset neuronal lipofuscinosis (Batten disease), possibly due to reduced au-
tophagosome/lysosome fusion. 
Vesa and Peltonen, 
2002
LAMP-2a Familial X-linked cardiomyopathy (Danon disease), possibly due to reduced autophago-
some/lysosome fusion.
Nishino et al., 2000
Examples of Gene Products that Regulate Autophagy and Other Cellular Processes
AKT, PI3K, PTEN (somatic) Cancer. Gain-of-function mutations or (somatic) amplifications in the oncogenes PI3K 
and Akt and loss-of-function mutations in the tumor suppressor gene PTEN confer 
autonomy from growth factors and inhibit autophagy.
Cully et al., 2006
TSC1, TSC2 (germline and 
somatic)
Tuberous sclerosis complex (autosomal dominant disorder with benign hamartomatous 
growths in multiple organs). Mutations in TSC1 or TSC2 abolish their inhibition of mTOR, 
leading to decreased autophagy.
Schwartz et al., 2007
LKB1/STK11 (germline and 
somatic)
Peutz-Jeghers syndrome (autosomal dominant syndrome with benign hamartomatous 
polyps in gastrointestinal tract and increased incidence of epithelial cancers). Somatic 
mutations in non-small cell lung cancer. LKB1 activates AMPK and stimulates  autophagy.
Ji et al., 2007; Liang et 
al., 2007
p53 (somatic) Cancer. Mutations in p53 mutations are found in >50% of all human tumors. p53 may 
activate autophagy after genotoxic stress.
Feng et al., 2005;  
Crighton et al., 2006
Bcl-2 (somatic) Follicular lymphoma. Amplification of Bcl-2 may inhibit autophagy by targeting Beclin 1. Pattingre et al., 2005
IRGM1 (germline) Crohn’s diease (a type of inflammatory bowel disease). IRGM1 is an immunity-related 
GTPase that stimulates autophagy.
Massey and Parkes, 
2007
aIndicates that mice harboring identical mutations have been shown to have impaired autophagy and display similar disease phenotype (see Table 
1 for details).Beyond its role in the clearance of misfolded proteins spon-
taneously generated during routine protein turnover (discussed 
above), autophagy likely plays an important role in the clear-
ance of aggregate-prone mutant proteins associated with 
several different neurodegenerative diseases (Figure 3). These 
include proteins with polyglutamine (polyQ) expansion tracts 
such as those seen in Huntington’s disease and spinocerebel-
lar ataxia, mutant α-synucleins that cause familial Parkinson’s 
disease, and different forms of tau including mutations causing 
frontotemporal dementia (Williams et al., 2006). Because sub-
strates need to be unfolded to pass through the narrow pore 
of the proteasomal barrel, oligomeric and aggregated proteins 
are poor substrates for proteasomal degradation and better 
targets for autophagic degradation. The mechanism by which 
these proteins exert their cellular toxicity is still controversial, 
but it is generally believed that they are particularly toxic in 
oligomeric complexes and that higher-order protein aggre-
gates may be formed as a last attempt to prevent toxicity in 
the absence of a properly functioning quality-control system 
(Martinez-Vicente and Cuervo, 2007). This view is consistent 
with the model that autophagy functions as a quality-control 
system that targets oligomeric proteins and with the evidence that autophagy activation reduces, whereas autophagy inhi-
bition increases, the formation of protein aggregates and the 
neurotoxicity of aggregate-prone proteins.
Pharmacological activation of autophagy reduces the levels 
of soluble and aggregated forms of mutant huntingtin protein, 
proteins mutated in spinocerebellar ataxia, mutant forms of 
α-synuclein, and mutant tau; it also reduces their cellular toxicity 
in vitro and their neurotoxicity in either mouse or Drosophila mod-
els (Rubinsztein et al., 2007). ATG gene knockdown or knockout 
increases aggregate formation and toxicity of polyQ expansion 
proteins in C. elegans (Jia et al., 2007). Autophagy induced by 
overexpression of histone deacetylase 6 also compensates for 
impairment in the ubiquitin-proteasome system in a fly model 
of spinobulbar muscle dystrophy (Pandey et al., 2007). In these 
models, autophagy-mediated neuroprotection may be due to a 
quantitative reduction in the amounts of the toxic protein species 
as well as antiapoptotic effects (Rubinsztein et al., 2007).
The development of neurodegenerative disease in patients 
with proteinopathies implies that the autophagy may reach a 
saturation point in which its capacity to degrade the mutant 
aggregate-prone proteins is exceeded, or that concurrent 
defects may occur in the autophagy pathway. Acquired defects Cell 132, January 11, 2008 ©2008 Elsevier Inc. 33
in autophagosome formation may result from the sequestration 
of autophagy proteins in aggregates formed by mutant proteins, 
the age-related decline that occurs in Beclin 1 and potentially 
other autophagy protein expression in human brain, and other 
as-of-yet unidentified factors (Shibata et al., 2006). In addition to 
defects that result in decreased autophagic activity, genetic or 
functional alterations may occur that impair delivery of autopha-
gosomes to the lysosome. For example, mutations that affect 
the dynein motor machinery impair autophagosome-lysosome 
fusion, leading to decreased autophagic clearance of aggregate 
proteins and enhanced toxicity of the huntingtin mutant protein in 
Drosophila and mouse models (Ravikumar et al., 2005). It is thus 
possible that impaired autophagic clearance may contribute to 
the pathogenetic mechanism by which dynein mutations cause 
motor neuron diseases in humans (Table 2). Other mutations 
involved in lysosomal function also reduce autophagic turnover 
(with an observed increase in autophagosomal accumulation) 
and are associated with neuronal ceroid lipofuscinosis (Bat-
ten disease) in mice, such as CLN3 partial deletion, cathepsin 
D knockout, and double cathepsin B/L knockout (Table 1). The 
interrelationship between autophagy and Alzheimer’s disease 
may also involve an impairment in autophagolysosomal matura-
tion. Autophagosome-like structures accumulate in dystrophic 
neurons of Alzheimer’s disease patients, presumably as a result 
of impairment in autophagolysosomal maturation and, intrigu-
ingly, may constitute a unique site of production/accumulation 
of the pathogenic amyloid β protein (Yu et al., 2005).
The role of autophagy in protection against neurodegenera-
tive diseases is established in animal models but not yet in 
patients. Nonetheless, preclinical animal data provide a strong 
rationale for proceeding with clinical trials with autophagy-
stimulatory agents; this is especially true as agents shown to 
be beneficial in reducing neurotoxicity of mutant aggregate-
prone proteins are already in clinical use to treat other dis-
eases. Rapamycin analogs, which are approved for the use of 
preventing organ transplant rejection and postangioplasty cor-
onary artery restenosis and are in phase II oncology trials, pro-
tect against neurodegeneration seen in Drosophila and mouse 
polyQ disease models (Rubinsztein et al., 2007). However, 
because TOR also affects protein synthesis, cell proliferation, 
cell growth, cell death, and immune function, its inhibition has 
some adverse effects; perhaps intermittent rather than con-
tinuous stimulation of autophagy with rapamycin may reduce 
such side effects while maintaining therapeutic efficacy. Lith-
ium chloride, a drug used for the treatment of bipolar disor-
der, induces autophagy by reducing IP3 levels and enhances 
the clearance of aggregate-prone proteins (Rubinsztein et al., 
2007). Another group of new agents, small molecule enhancers 
of rapamycin (SMERs), enhance the clearance of mutant hun-
tingtin and α-synuclein and protect against neurodegeneration 
in a Drosophila Huntington’s disease model (Sarkar et al., 2007). 
Given that lithium and SMERs both act independently of TOR, 
it is possible that they may be used therapeutically in combina-
tion with rapamycin analogs. Of long-term interest, both for the 
treatment of neurodegenerative diseases and, potentially, the 
prevention of aging, would be drugs that can reverse age-de-
pendent declines that occur in CNS autophagy protein expres-
sion and lysosomal clearance of autophagosomes.34 Cell 132, January 11, 2008 ©2008 Elsevier Inc.Autophagy and Liver Disease
Tissue-specific knockout studies in mice (discussed above) 
indicate an important role for basal hepatocyte autophagy in 
intracellular protein and organelle quality control. The protein 
quality-control function may be important in the pathogenesis 
of the most common genetic cause of human liver disease, 
α1-antitrypsin deficiency, which is associated with chronic 
inflammation and carcinogenesis (Perlmutter, 2006). Perhaps, 
similar to neurodegenerative disorders caused by aggregate-
prone proteins, pharmacological activation of autophagy may 
be helpful in this setting.
A toxic gain-of-function point mutation in α1-antitrypsin Z 
(α1-ATZ) impairs proper protein folding and renders a normally 
secreted hepatic protein prone to form aggregated polymers 
within the hepatocyte ER. Whereas wild-type α1-antitrypsin 
is degraded primarily by the proteasome, mutant α1-ATZ is 
thought to be degraded primarily by autophagy (Yorimitsu and 
Klionsky, 2007). In cell lines depleted of atg5, there is decreased 
degradation of the mutant α1-ATZ, especially insoluble forms, 
and increased accumulation of cytoplasmic inclusion bodies 
(Kamimoto et al., 2006). Moreover, transgenic expression of 
α1-ATZ is sufficient to induce mouse hepatocyte autophagy in 
vivo. The precise role of α1-ATZ aggregates in hepatotoxicity is 
not yet clear; one interesting question is whether such aggre-
gates sequester autophagy proteins, leading to a reduction in 
hepatocyte autophagy (and its cytoprotective and tumor sup-
pressor effects). A broader question of biomedical relevance is 
whether the protein quality-control function of autophagy plays 
a more general role in protecting the liver against alcohol and 
other hepatotoxic agents.
Autophagy and Muscle Disease
Similar to neurodegenerative diseases, the pathogenesis of 
myodegenerative diseases may involve either the failure of 
autophagosomes to fuse with lysosomes or the aggregation 
of misfolded proteins that exceed the autophagic clearance 
capacity of the myocyte. Danon disease, a genetic disease 
characterized by cardiomyopathy, myopathy, and variable 
mental retardation, results from a mutation in the lysosomal 
protein LAMP-2 and is associated with extensive accumula-
tion of autophagosomes in the muscles of LAMP-2-deficient 
mice and patients (Tables 1 and 2). The concept that failure of 
lysosomes to fuse with autophagosomes contributes to myo-
pathy is further supported by evidence that pharmacological 
inhibition of this fusion step (e.g., with chloroquine or hydroxy-
chloroquine) causes severe vacuolar myopathies in rats and 
humans (Bolanos-Meade et al., 2005). There are several other 
histologically related diseases, such as X-linked myopathy with 
excessive autophagy, infantile autophagic vacuolar myopa-
thy, adult-onset vacuolar myopathy with multiorgan involve-
ment, and X-linked congenital autophagic vacuolar myopathy, 
that have unclear molecular defects (Nishino, 2006); however, 
the prediction is that these disorders may be due, at least in 
part, to an impairment in autophagosome-lysosome fusion. 
Another severe inherited disorder of skeletal and cardiac 
muscle, Pompe disease, which is caused by the deficiency of 
glycogen-degrading lysosomal enzyme acid α-glucosidase 
(GAA), is often resistant to GAA enzyme replacement in skel-
etal muscle but not in heart (Fukuda et al., 2006). Endocytic 
trafficking of recombinant GAA is abnormal in skeletal muscle; 
it accumulates primarily in autophagosomes and fails to reach 
the lysosomal compartment, providing an example of how the 
”traffic jam” provoked by defective lysosomal function may be 
pathogenic.
Muscle diseases in which autophagy may promote the 
clearance of disease-causing proteins include sporadic inclu-
sion body myositis, limb girdle muscular dystrophy type 2B, 
and Miyoshi myopathy. In sporadic inclusion body myositis, 
the most common acquired muscle disease in patients above 
50 years of age, overexpression of amyloid precursor protein 
(APP) and accumulation of its proteolytic fragment β-amyloid in 
vacuolated cells is thought to be a central pathogenetic mech-
anism (Askanas and Engel, 2006). Both APP and β-amyloid 
colocalize with LC3 in cultured human muscle cells and in 
degenerating muscle fibers in human biopsy tissue, suggest-
ing that these proteins are cleared by autophagy (Lunemann et 
al., 2007). Limb girdle muscular dystrophy type 2B and Miyoshi 
myopathy are both caused by mutations of the gene encoding 
dysferlin, a type II transmembrane protein expressed primar-
ily in muscle sarcolemma. Although wild-type dysferlin in the 
ER is degraded primarily by the ubiquitin-proteasome system, 
mutant dysferlin, which spontaneously aggregates in the ER, 
is degraded primarily by the autophagy/lysosomal system 
(Askanas and Engel, 2006). In cells expressing mutant dysfer-
lin, autophagy inhibition due to atg5 depletion or a mutation 
in the ER-stress-induced eIF2α-mediated autophagy path-
way increases aggregation whereas rapamycin activation of 
ER-stress-induced autophagy decreases aggregation. Thus, 
a general theme seems to be emerging in diseases associ-
ated with aggregate-prone proteins not only in the brain but 
also in the liver and muscle; the autophagy pathway plays a 
central role in the clearance of such proteins, and pharmaco-
logic upregulation of autophagy may protect against aggregate 
accumulation.
Autophagy and Cardiac Disease
As noted, defective autophagy (due to impaired autopha-
gosome-lysosome fusion) may play a role in relatively rare 
forms of inherited diseases of the heart (e.g., Danon disease, 
Pompe disease). Of greater medical significance is the pos-
sibility that autophagy may constitute an important physi-
ological or pathophysiological response to cardiac stresses 
such as ischemia or pressure overload, which are frequently 
encountered in patients with coronary artery disease, hyper-
tension, aortic valvular disease, and congestive heart failure. 
The accumulation of autophagosomes has been noted in car-
diac biopsy tissues of patients with these disorders, rodent 
models of these cardiac diseases, and isolated stressed 
cardiomyocytes (Terman and Brunk, 2005). Prior to genetic 
studies, it was largely assumed that autophagy invariably 
contributed to myocyte degeneration in such settings. How-
ever, more recent data challenge this view; the cytoprotective 
effects of autophagy (either via ATP production, protein and 
organelle quality control, or other mechanisms) may predomi-
nate in certain settings.
The cardiomyocyte, similar to the neuron, is a postmitotic cell 
in which basal autophagy may be important in protein and organ-
elle quality control. Heart-specific knockout of atg5 in adult mice results in cardiac hypertrophy and contractile dysfunction that is 
accompanied by increased levels of ubiquitinated proteins and 
ultrastructural evidence of sarcomere and mitochondrial struc-
tural abnormalities (Table 1). Beyond this need for autophagy 
under basal conditions, the heart may uniquely rely on stress-
induced upregulation of autophagy to ensure the availability of 
energy substrates and to promote cellular remodeling. The heart 
consumes more energy per gram than any other organ in the 
body, and common cardiac disorders (e.g., cardiac ischemia and 
heart failure) are characterized by a reduction in the availability of 
energy substrates, a factor that contributes to transient or sus-
tained impairment of cardiac function. Furthermore, when cardiac 
stresses are sustained for long periods of time, myocytes remodel 
their cellular architecture (e.g., undergo elongation and hyper-
trophy) to adapt to stress. The needs of the stressed heart for 
more energy substrates and for cellular remodeling may be met in 
part through the autophagy pathway; cardiac-specific deficiency 
of atg5 early in cardiogenesis does not result in any phenotypic 
abnormalities under basal conditions but results in more severe 
cardiac dysfunction following treatment with pressure overload or 
β-adrenergic stress (Table 1) . These data suggest that upregula-
tion of autophagy in failing hearts is an adaptive response that 
protects against hemodynamic or neurohormonal stresses.
Although this is an attractive model, not all studies support an 
adaptive role for autophagy during cardiac stress. In a pressure 
overload model, heterozygous disruption of beclin 1 led to pres-
ervation not deterioration of contractile function (Table 1). These 
results differ from those obtained in atg5 knockout mice, which 
may reflect different contributions of atg5 versus beclin 1 or dif-
ferent effects of homozygous versus heterozygous disruption of 
an ATG gene. Heterozygous disruption of beclin 1 also decreases 
the size of the myocardial infarction after ischemia/reperfusion 
(Table 1). However, in an in vitro model of cardiac ischemia/rep-
erfusion, beclin 1 overexpression decreased cell injury and domi-
nant-negative Atg5 overexpression increased cell injury, suggest-
ing a protective effect for both ATG genes in ischemia/reperfusion 
(Hamacher-Brady et al., 2006). Additional studies are needed to 
clarify whether autophagy activation serves as an adaptive or mal-
adaptive cardiac response to hemodynamic and ischemic stress. 
It is noteworthy, however, that in patients, interventions known to 
exacerbate ischemia or heart failure (e.g., beta-adrenergic recep-
tor agonists) act to reduce autophagy in the heart whereas inter-
ventions known to ameliorate ischemia or heart failure (e.g., beta-
adrenergic receptor antagonists) tend to enhance autophagy in 
the heart (Bahro and Pfeifer, 1987).
Autophagy and Cancer
In the past decade, several genetic links have emerged between 
autophagy defects and cancer, providing increasing support 
for the concept that autophagy is a bona fide tumor suppressor 
pathway (Levine, 2007; Mathew et al., 2007a).
The regulation of autophagy overlaps closely with signaling 
pathways that regulate tumorigenesis. Several tumor suppres-
sor genes involved in the upstream inhibition of TOR signal-
ing, including PTEN, TSC1, and TSC2, stimulate autophagy 
and, conversely, TOR-activating oncogene products such as 
class I PI3K and Akt inhibit autophagy (Table 2). P53, the most 
commonly mutated tumor suppressor gene in human can-
cers, positively regulates autophagy in DNA-damaged cells, Cell 132, January 11, 2008 ©2008 Elsevier Inc. 35
perhaps through AMPK activation of the TSC1/TSC2 complex 
and subsequent TOR inhibition or perhaps via upregulation of 
DRAM (damage-regulated autophagy modulator), a lysosomal 
protein that may induce autophagy (Crighton et al., 2006; Feng 
et al., 2005). The death-associated protein kinase, DAPk, also 
induces autophagy and apoptosis, is commonly silenced in 
human cancers by methylation, and has tumor and metasta-
sis suppressor properties (Gozuacik and Kimchi, 2006). The 
cellular proto-oncoproteins, Bcl-2 and Bcl-XL, which are often 
overexpressed in human cancers, are generally thought to 
mediate oncogenesis by suppressing mitochondrial mem-
brane permeabilization, one of the rate-limiting steps of 
apoptosis. In addition, ER-localized Bcl-2 and Bcl-XL inhibit 
autophagy by binding to the Beclin 1 autophagy protein (Pat-
tingre et al., 2005; Maiuri et al., 2007b). Thus, there is a strong 
correlation between molecules that are involved in autophagy 
induction and tumor suppression and between molecules that 
are involved in autophagy inhibition and oncogenesis. It will 
be important to determine whether this autophagy modulation 
is mechanistically important in the action of these tumor sup-
pressor genes and oncogenes. Such a finding would suggest a 
broad involvement of autophagy in most human cancers.
The first specific link between the autophagy machinery and 
human cancer was established in 1999, when it was discov-
ered that the ATG gene beclin 1 was a candidate tumor sup-
pressor (Liang et al., 1999). Beclin 1 maps to a tumor suscepti-
bility locus that is monoallelically deleted in a high percentage 
of human breast, ovarian, and prostate cancers (Table 2), and 
decreased expression of Beclin 1 has been reported in human 
breast, ovarian, and brain tumors (Liang et al., 1999; Miracco 
et al., 2007). Beclin 1 gene transfer inhibits growth of tumor cell 
lines in vitro and the tumorigenicity of human breast carcinoma 
cells in mouse xenograft models (Liang et al., 1999). The mono-
allelic deletions of beclin 1 in human cancer are likely mechanis-
tically important in tumorigenesis, given that targeted mutant 
mice with heterozygous disruption of beclin 1 have decreased 
autophagy, are more prone to the development of spontane-
ous tumors including lymphomas, lung carcinomas, hepato-
cellular carcinomas, and mammary precancerous lesions, and 
undergo accelerated hepatitis B virus-induced carcinogenesis 
(Table 1). Further, immortalized kidney and mammary epithe-
lial cells derived from beclin 1 heterozygous-deficient mice 
are more tumorigenic than those derived from wild-type mice 
(Karantza-Wadsworth et al., 2007; Mathew et al., 2007b).
The Mittleman Breakpoint Database reveals frequent chromo-
somal aberrations of several other components of the autophagic 
machinery in human cancers, although it is not yet known if these 
components are biallelically mutated or function as haploinsuf-
ficient tumor suppressors. Atg5, a component of the ubiquitin-
like protein conjugation system, has tumor suppressor effects 
in a mouse xenograft model (Yousefi et al., 2006), and knock-
out of atg4c, a cysteine protease involved in processing LC3, 
increases chemically induced fibrosarcomas in mice (Table 1). 
This suggests that tumor suppression may be a shared property 
of autophagy proteins that act at different steps in the pathway. 
Other proteins that form part of the Beclin 1/class III PI3K complex 
and are required for its autophagy activity may also play a role in 
cell growth control and/or tumor suppression. UVRAG, originally 36 Cell 132, January 11, 2008 ©2008 Elsevier Inc.identified through its ability to complement UV-radiation sensitiv-
ity in tumor cells, is monoallelically deleted at a high frequency in 
human colon cancers and suppresses the proliferation and tum-
origenicity of human colon cancer cells (Liang et al., 2006). Bif-1 
interacts with Beclin 1 through UVRAG and activates the Beclin 
1/class III PI3K complex, and its deletion in mice results in the 
development of spontaneous tumors (Table 1). Another compo-
nent of the complex that positively regulates autophagy, Ambra1, 
has only been studied in the context of CNS development, but 
ambra1 deficiency in mouse embryos leads to severe neural tube 
defects associated with autophagy impairment and uncontrolled 
cell proliferation (Table 1), further supporting the concept that the 
Beclin 1/class III PI3K complex regulates cell growth.
The genetic links between deficiencies in the autophagy 
machinery and tumor susceptibility highlight the likely impor-
tance of autophagy in tumor suppression. However, the molecu-
lar mechanisms by which autophagy functions in tumor suppres-
sion are poorly defined. Increasing evidence suggests that the 
tumor suppressor functions of autophagy may be independent 
of both potential prodeath and prosurvival effects (Mathew et al., 
2007a). Epithelial tumors that arise from cells with monoallelic or 
biallelic deletions of beclin 1 or atg5, respectively, do not display 
decreased cell death; in fact, in regions of metabolic stress, they 
display increased cell death, as would be expected with loss 
of autophagy-dependent survival (Mathew et al., 2007b). The 
association between increased cell death and increased tum-
origenic potential in the setting of ATG gene deficiency suggests 
that autophagy-dependent survival, at least in certain experi-
mental models, does not promote tumorigenesis. White and col-
leagues have proposed two hypotheses to explain how loss of 
autophagy, a cell survival pathway, may stimulate oncogenesis. 
First, when tumor cells cannot die by apoptosis upon exposure 
to metabolic stress, autophagy may prevent death from necrosis, 
a process that might exacerbate local inflammation and thereby 
increase tumor growth rate (Degenhardt et al., 2006). Second, 
ATG gene deletion may promote genomic instability in metaboli-
cally stressed cells, leading to oncogene activation and tumor 
progression (Mathew et al., 2007a). Indeed, immortalized mouse 
epithelial cells with ATG gene deficiency (monoallelic loss of 
beclin 1 or biallelic loss of atg5) display increased DNA damage, 
centrosome abnormalities, aneuploidy, numerical and structural 
chromosomal abnormalities, and gene amplification, espe-
cially during ischemic stress that is associated with increased 
tumorigenicity. These cells are engineered to have concurrent 
defects in cell-cycle checkpoints and apoptosis (e.g., p53 and 
Rb inactivation, Bcl-2 overexpression); thus, it is not yet known 
whether autophagy prevents genomic instability in normal cells 
and thereby plays a role in preventing tumor initiation.
Another possibility is that autophagy plays a more direct 
role in negative growth control, perhaps by degrading specific 
organelles or proteins essential for cell growth regulation. In 
support of this theory, enforced Beclin 1 expression slows the 
proliferation of tumor cell lines (without affecting cell death) 
and causes a decrease in expression of cyclin E and phos-
phorylated Rb (Koneri et al., 2007; Liang et al., 1999). Also, 
mice with a monoallelic deletion of beclin 1 display hyperpro-
liferation of both mammary epithelial cells and splenic lym-
phocytes (Qu et al., 2003). In Drosophila, overexpression of 
Atg1, which causes the hyperactivation of autophagy, directly 
inhibits cell growth and induces cell death (Scott et al., 2007). 
In the nematode, caloric restriction and insulin-signaling 
mutations that increase autophagic activity reduce tumor cell 
division, although it is not yet known whether these antipro-
liferative effects are mediated by autophagy (Pinkston et al., 
2006). One hypothesis is that, despite its prosurvival effects, 
autophagy activation in tumor cells by metabolic stress pre-
vents inappropriate cell division. The spontaneous prolifera-
tion of normally quiescent mammary epithelial cells in beclin 
1+/− mice suggests that autophagy (similar to TOR inhibition) 
plays a role in coordinating environmental cues and entry or 
maintenance of the G0 state.
Although it is presently unclear whether cell survival/cell 
death effects are relevant to the tumor suppressor role of 
autophagy, such effects are likely important in cancer thera-
peutics. A large series of clinically approved and experimental 
anticancer therapies induce the accumulation of autophago-
somes in tumor cell lines in vitro (Maiuri et al., 2007a). For many 
years, it was thought that these therapies kill cells through 
autophagy (i.e., induce “autophagic cell 
death”). However, specific inhibition of 
autophagy with siRNAs targeted against 
ATG genes usually accelerates, rather 
than prevents, cell death in these set-
tings (Maiuri et al., 2007a), indicating 
that autophagy activation represents 
a cellular attempt to cope with stress 
induced by cytotoxic agents. This sug-
gests that inhibition of autophagy (rather 
than stimulation of autophagy) might be 
beneficial in cancer treatment. Indeed, 
in mice harboring c-Myc-induced lym-
phomas, the drug chloroquine, an alka-
linizing lysosomotropic drug that impairs 
autophagic degradation, enhanced the 
ability of either p53 or a DNA alkylat-
ing agent to induce tumor cell death 
and tumor regression (Amaravadi et al., 
2007), indicating a potential prosurvival 
and protumorigenic role for autophagy 
during cancer chemotherapy. Because 
chloroquine has pleiotropic effects, both on tumor cells (for 
instance on the multidrug pump) and on the host immune sys-
tem (where it stimulates antitumor responses; Apetoh et al., 
2007), it may be premature to explain its antitumor effects 
solely via its autophagy inhibitory action. Further in vivo stud-
ies are needed with more specific inhibitors of autophagy to 
determine whether the beneficial effects of blocking a tumor 
cell survival pathway outweigh the potential detrimental effects 
of blocking a tumor suppressor pathway.
Autophagy and Aging
The notion that intermittent fasting promotes longevity is not 
merely a cultural belief shared by diverse civilizations through-
out history; it is a scientific truth that extends across eukaryotic 
organisms, including yeast, flies, worms, and rodents (Guar-
ente and Kenyon, 2000). Dietary restriction is a potent inducer 
of autophagy in virtually all species (Levine and Klionsky, 2004). 
In the model organism, C. elegans, autophagy is required for 
the life-extending effects of dietary restriction; feeding-defec-
tive worms do not live longer if treated with siRNA against atg 
genes (Jia and Levine, 2007). A similar requirement exists for 
Figure 4. Autophagy in Innate and Adaptive 
Immunity
In xenophagy, intracellular pathogens (bacteria, 
protozoans, and viruses) that are either inside the 
cytosol or in pathogen-containing vacuoles are 
surrounded by isolation membranes, engulfed into 
autophagosomes, and degraded inside autolyso-
somes. Autophagy may be involved in the activa-
tion of innate immunity by delivering viral nucleic 
acids to endosomal compartments containing Toll-
like receptor 7 (TLR7), which signals the induction 
of type 1 interferon (IFN) production. Autophagy 
may be involved in adaptive immunity by deliver-
ing endogenously synthesized microbial antigens 
and self-antigens to late endosomes, where they 
are loaded onto MHC class II molecules for pre-
sentation to CD4+ T cells.Cell 132, January 11, 2008 ©2008 Elsevier Inc. 37
atg genes in the longevity phenotype of worms with a loss-
of-function mutation in the insulin/IGF-1 signaling pathway 
(Melendez et al., 2003), a hormonal pathway that negatively 
regulates autophagy and life span in diverse species. Interest-
ingly, dietary-restricted or long-lived insulin/IGF-1 mutants are 
resistant to many age-related diseases, including Huntington’s 
disease and cancer in C. elegans disease models, sarcopenia 
in worms, heart failure in Drosophila, and cancer in rodents 
(Kenyon, 2005). In view of the protective role of autophagy 
in certain age-related diseases such as neurodegeneration, 
cardiomyopathy, and cancer, a critical question is whether 
autophagy activation in long-lived mutant animals is mecha-
nistically responsible for resistance to age-related disease.
A corollary question is whether autophagy function declines 
with age, and if so, whether such a decline contributes to aging 
and susceptibility to age-related diseases. Indeed, both clas-
sical autophagy (macroautophagy) and chaperone-mediated 
autophagy decline with aging in rodents and probably in 
humans (Martinez-Vicente and Cuervo, 2007). The mecha-
nism for the decline in autophagy with aging is unknown but, 
at least in the rodent liver, is thought to involve alterations both 
in responses to hormonal regulation of autophagy (e.g., gluca-
gon, insulin) and in the degradation of autophagosomes (Del 
Roso et al., 2003). It is possible that the accumulation of undi-
gested material inside secondary lysosomes—a characteristic 
feature of aged, postmitotic cells—interferes with the ability of 
lysosomes to fuse with autophagosomes and degrade their 
cargo, thus creating a vicious cycle leading to a progressive 
defect in autophagosome degradation. However, it is equally 
plausible that this feature of aging results from, rather than 
causes, autophagy impairment. It will be important to further 
determine what age-related changes occur in the expression 
or function of proteins directly involved in autophagy regulation 
and execution or in lysosomal function.
A cardinal feature of aging postmitotic cells is the accumula-
tion of damaged proteins and organelles—especially function-
ally disabled mitochondria and lipofuscin-loaded lysosomes. 
Mutations that decrease mitochondrial metabolism or reduce 
levels of reactive oxygen species extend life span in C. ele-
gans and rodents, presumably by decreasing the generation of 
damaged proteins and organelles (Levine and Klionsky, 2004). 
In parallel, the activation or inhibition of autophagy likely pre-
vent or promote aging, respectively, due to alterations in the 
removal of damaged proteins and organelles. As noted above, 
tissue-specific deletion of ATG genes in postmitotic cells, 
including neurons, hepatocytes, and cardiomyocytes, reveals 
a critical role for basal autophagy in protein and organelle turn-
over and prevention of cellular degeneration. Therefore, it is 
easy to imagine how either the cumulative effects of incom-
plete autophagic clearance over prolonged periods and/or 
age-related declines in autophagy function could contribute to 
aging. Caloric restriction can extend life span in diverse species 
and reverse the age-related decline in autophagy in rodent liver 
(Kenyon, 2005). Yet, despite the practice of fasting to promote 
longevity throughout human history, alternative approaches 
should be sought that mimic the beneficial effects of caloric 
restriction on autophagy while avoiding the potential adverse 
effects of caloric restriction on other aspects of human health. 38 Cell 132, January 11, 2008 ©2008 Elsevier Inc.One such candidate is an antilipolytic drug that has been used 
successfully to increase autophagic activity in rodent liver and 
to extend life span (Bergamini, 2005). The life-span effects of 
other clinically used autophagy inducers such as rapamycin 
and lithium chloride have not been investigated. Ideally, the 
molecular basis for the age-related decline in autophagy func-
tion should be identified and pharmacologically targeted.
Autophagy in Infection, Immunity, and Inflammatory 
Diseases
The autophagic machinery is used in a multipronged defense 
against microbes, including the selective delivery of microor-
ganisms to degradative lysosomes (a process referred to as 
xenophagy) and the delivery of microbial nucleic acids and 
antigens to endo/lysosomal compartments for activation of 
innate and adaptive immunity (see Levine and Deretic, 2007; 
Schmid and Munz, 2007 for detailed reviews) (Figure 4). Numer-
ous medically important pathogens are degraded in vitro by 
xenophagy, including bacteria such as group A Streptococ-
cus, Mycobacterium tubercuolosis, Shigella flexneri, Salmo-
nella enterica, Listeria monocytogenes, Francisella tularensis; 
viruses such as herpes simplex virus type I (HSV-1); and para-
sites such as Toxoplasma gondii. It is predicted that xenophagy 
participates in pathogen protection in vivo, but data supporting 
this are limited to certain viral diseases such as tobacco mosaic 
virus in plants and HSV-1 and Sindbis virus in mice (Levine and 
Deretic, 2007). With the availability of tissue-specific ATG gene 
knockout mice, it should be possible to more broadly evaluate 
the role of xenophagy in microbial pathogenesis.
Recent studies also indicate that autophagy participates 
in trafficking events that activate innate and adaptive immu-
nity (Levine and Deretic, 2007; Schmid and Munz, 2007). With 
respect to innate immunity, atg5 is required for the delivery 
of viral nucleic acids from Sendai virus and vesicular stoma-
titis virus to the endosomal toll-like receptor (TLR), TLR7, and 
subsequent activation of type I interferon signaling in plas-
macytoid dendritic cells (Table 1). With respect to adaptive 
immunity, autophagy is involved in the delivery of certain 
endogenously synthesized microbial antigens (e.g., Epstein 
Barr viral antigens) to MHC class II antigen-presenting mol-
ecules, leading to the activation of CD4+ T lymphocytes. The 
selective targeting of other viral antigens, such as the influ-
enza virus matrix protein, to the autophagosome by fusion 
with LC3 results in dramatic enhancement of CD4+ T lympho-
cyte responses. Although it is not yet known how universally 
important the contribution of autophagic delivery of microbial 
antigens is in adaptive immunity during natural infections, this 
latter finding has immediate implications for vaccine devel-
opment; targeting proteins for autophagic delivery to MHC 
class II loading compartments may be an effective means to 
improve T helper cell responses and thereby increase vac-
cine efficacy. Not only does the autophagic machinery func-
tion in innate and adaptive immunity, but several innate and 
adaptive immune mediators involved in intracellular pathogen 
control stimulate autophagy, including the interferon-induc-
ible antiviral molecule, PKR; CD40-CD40 ligand interactions; 
IFNγ and its downstream immunity-related GTPases; TNFα; 
T-helper type 1 lymphocytes; and the cell-surface receptor, 
TLR4 (Levine and Deretic, 2007).
Given the likely importance of autophagy in host defense 
against intracellular pathogens, microbial virulence may be 
partly determined by the ability of such pathogens to suc-
cessfully antagonize host autophagy. Moreover, for organisms 
such as bacteria that can replicate outside of host cells, the 
ability to antagonize autophagy may influence whether or not 
the organism is an extracellular or intracellular pathogen. For 
example, group A Streptococcus is an extracellular pathogen 
that invades into the cytoplasm of epithelial cells but is rapidly 
degraded by an autophagy-dependent pathway (Nakagawa et 
al., 2004). Successful intracellular microbes may antagonize 
both the signaling pathways that activate autophagy as well as 
the membrane trafficking events required for lysosomal deliv-
ery and degradation, either indirectly or directly by inhibitory 
interactions with autophagy proteins (see Levine and Deretic, 
2007 for detailed review). Perhaps the most compelling evi-
dence to date that microbial evasion of autophagy is important 
for disease is a recent study with HSV-1; the ability of the virus 
to cause fatal encephalitis in mice is severely compromised by 
a mutation in a virally encoded neurovirulence factor that abro-
gates its ability to bind to Beclin 1 and inhibit host autophagy 
(Orvedahl et al., 2007). Thus, whereas host-related factors 
that contribute to autophagy impairment (e.g., mutations in 
genes involved in autophagy or lysosomal function, epige-
netic changes that affect autophagolysomsomal trafficking) 
may contribute to susceptibility to certain other diseases (e.g., 
neuro- and myodegenerative disorders and aging), microbes 
may be able to successfully disarm even an optimally function-
ing host autophagy system to cause pathology. The selective 
disruption of interactions between microbial virulence fac-
tors and their targeted host autophagy proteins represents an 
attractive new antimicrobial therapeutic strategy.
Autophagy has additional effects on immunity that are not 
directly relevant to pathogen control (reviewed in Levine and 
Deretic, 2007). The role of autophagy in cellular homeosta-
sis and life and death decisions may extend to T lymphocyte 
development and to T lymphocyte depletion during HIV infec-
tion. CD4+ and CD8+ T cells from atg5−/− mice fail to undergo 
efficient proliferation after T cell receptor stimulation. Upon 
transplantation into lethally irradiated mice, atg5−/− lympho-
cytes develop normally in the thymus but fail to repopulate 
the periphery due to overwhelming cell death (Table 1). One 
interpretation of this finding is that T cells, upon exit from the 
thymus, become exposed to nutritional stress due to limita-
tions in trophic factor support and require autophagy for sur-
vival. In contrast, another study found that TH2 cells become 
more resistant to cell death induced by growth-factor with-
drawal when autophagy is blocked using pharmacological or 
genetic methods (Li et al., 2006). This cell death process may 
be exploited by viruses such as HIV, as the HIV envelope gly-
coprotein induces autophagic cell death by binding to CXC-
chemokine receptor 4 in uninfected bystander CD4+ T cells 
(Espert et al., 2006). Although only studied so far in the context 
of T cells, autophagy may also be involved in the homeostasis, 
differentiation, and function of other populations of immune 
cells. A particularly interesting question is whether autophagy 
plays a role in thymic selection and central tolerance. The role 
of autophagy in MHC class II presentation of self-antigens has not yet been directly examined, but the high levels of autophagic 
activity in the thymic epithelial cells of newborn mice (Mizush-
ima et al., 2004) suggests that autophagy may enable thymic 
epithelial cells to present self-antigens to lymphocytes during 
positive and negative selection.
The recently discovered function of autophagy in ATP-de-
pendent generation of engulfment signals and heterophagic 
removal of apoptotic corpses (Qu et al., 2007) hints at a poten-
tial role for autophagy in the prevention of inflammation and 
autoimmunity. The rapid removal of apoptotic corpses is criti-
cal for the prevention of tissue inflammation (Grossmayer et al., 
2005), and indeed, autophagy-deficient atg5−/− embryos have 
increased inflammation in tissues that have impaired clear-
ance of apoptotic cells (Qu et al., 2007). Moreover, the lack of 
efficient apoptotic cell clearance may overcome tolerance to 
self-antigens and lead to autoimmune diseases such as sys-
temic lupus erythematosis (SLE) (Grossmayer et al., 2005). It is 
therefore possible that defective autophagy may contribute to 
the pathogenesis of SLE or other autoimmune diseases.
Several recent genome-wide scans have uncovered 
strong genetic associations between two genes involved 
in autophagy, the autophagy-stimulatory immunity-related 
GTPase, IRGM1, and the autophagy execution gene, Atg16L, 
and susceptibility to Crohn’s disease, a chronic inflamma-
tory disease of the intestine (Table 2). These studies suggest 
a potential role for autophagy deregulation in the patho-
genesis of Crohn’s disease. However, as of yet, it is not 
known whether the ATG16L variant (T300A) is defective in 
autophagy function and whether this genetic link is indicative 
of an underlying mechanistic role of autophagy impairment 
in Crohn’s disease pathogenesis. The pathogenic mecha-
nisms of Crohn’s disease are incompletely understood but 
are postulated to involve a dysregulated immune response 
to commensal intestinal bacteria, altered mucosal barrier 
function, and/or defects in bacterial clearance (Baumgart 
and Carding, 2007). It is speculated that autophagy defi-
ciency might contribute to one or more of these pathological 
mechanisms in Crohn’s disease (Levine and Deretic, 2007). 
Studies in targeted mutant mice with conditional deletion of 
atg16 and other ATG genes should help elucidate potential 
interrelationships between alterations in autophagy and the 
pathogenesis of Crohn’s disease.
Conclusion
Based on new understandings of the physiological functions of 
autophagy we now know that both basal levels of autophagy 
and stress-induced increases in autophagy are likely important 
in promoting mammalian health. Autophagy maintains nutrient 
and energy homeostasis in the face of a limited food supply; it 
clears intracellular proteins and damaged organelles that may 
lead to tissue degeneration, genomic instability, cancer, and 
aging; and it defends mammalian cells against microbial attack. 
Perhaps this is why so many cultures have empirically incorpo-
rated periodic fasting, a practice that activates autophagy, into 
their healing traditions.
The activation of autophagy, however, is not without potential 
risks. Autophagy may help keep alive those cells that should 
die, such as chemotherapy-treated tumor cells, or, if present Cell 132, January 11, 2008 ©2008 Elsevier Inc. 39
in excess, kill cells that should live. If the lysosomal clearance 
of autophagosomes fails, the activation of autophagy results in 
a cellular traffic jam that may lead to increased pathology—a 
scenario that may in fact occur with aging, Parkinson’s dis-
ease, and other neuro- and myodegenerative disorders. Yet, in 
most diseases, we still do not fully understand how the poten-
tial risks of autophagy are weighed against its numerous adap-
tive physiological functions. The preponderance of currently 
available evidence from Drosophila, C. elegans, and mouse 
models does suggest that the primary function of autophagy 
may be to promote health and longevity. Nonetheless, fur-
ther research is needed to define the precise determinants of 
whether autophagy is beneficial or pathological in more spe-
cific disease contexts.
Clearly, we have learned and will continue to learn a great 
deal from autophagy-deficient model organisms. The criti-
cal question is whether these lessons translate into predicted 
insights regarding the roles of autophagy in human disease. 
This seems likely given the evolutionarily conserved nature of 
autophagy, the regulation of its signaling pathways, its molecu-
lar machinery, and its physiological functions, but formal proof 
is lacking. If our predictions from animal models are correct, 
we will need more specific ways to stimulate autophagy and 
the clearance of autophagosomes (for the prevention/treat-
ment of aging, infection, cancer, and degenerative diseases) 
as well as to inhibit autophagy (perhaps for cancer therapy). 
To accomplish this goal, we need a better understanding of 
the signaling control of autophagy, the molecular actions of 
the Atg proteins, the regulation of autophagosome/lysosome 
fusion, and the mechanistic basis for age-related and disease-
specific defects in autophagy activation and autophagolyso-
somal maturation. Perhaps then, we will be able to live longer 
and healthier lives—without having to fast.
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